Literature DB >> 979759

Prolonged antibiotic peritoneal lavage in the management of gross generalized peritonitis.

R C Atkins, D F Scott, S R Holdsworth, A J Davidson.   

Abstract

Since there is a high mortality and morbidity with conventional therapy in generalized peritonitis, a treatment regime of prolonged continuous peritoneal lavage (two to 10 days) with the lavage solution containing kanamycin (40 mug/ml) and cephalothin (100 mug/ml) was undertaken in 14 cases of gross, well established, diffuse peritonitis. Antibiotics were also given systemically. In 11 cases, in which the causative lesion was definitively repaired, no intraperitoneal complications developed and convalescence was rapid. Three patients, in whom causative lesion was not definitively repaired at operation, subsequently died. Prolonged antibiotic peritoneal lavage appears to be beneficial for patients with gross and diffuse peritoneal soiling, after the causative lesion has been repaired.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 979759

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  3 in total

Review 1.  Proposed definitions for diagnosis, severity scoring, stratification, and outcome for trials on intraabdominal infection. Joint Working Party of SIS North America and Europe.

Authors:  P O Nyström; R Bax; E P Dellinger; L Dominioni; W A Knaus; J L Meakins; C Ohmann; J S Solomkin; H Wacha; D H Wittmann
Journal:  World J Surg       Date:  1990 Mar-Apr       Impact factor: 3.352

2.  Pharmacology of intraperitoneal cefazolin in patients undergoing peritoneal dialysis.

Authors:  D Kaye; N Wenger; B Agarwal
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

3.  Irrigation of abdomen with imipenem solution decreases surgical site infections in patients with perforated appendicitis: a randomized clinical trial.

Authors:  Mohammad Ali Hesami; Hamid Alipour; Hamed Nikoupour Daylami; Bijan Alipour; Shahrzad Bazargan-Hejazi; Alireza Ahmadi
Journal:  Iran Red Crescent Med J       Date:  2014-04-05       Impact factor: 0.611

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.